Dream Finders Homes Buys Beazer Homes in $2.2 Billion Deal, Creating Sixth-Largest U.S. Builder
Dream Finders Homes acquires Beazer Homes for $33.50/share.
Already have an account? Sign in.
Dream Finders Homes acquires Beazer Homes for $33.50/share.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.